Capturing Value from Health Technologies in Lean Times

Ake Blomqvist, Colin Busby and Don Husereau
Additional contact information
Colin Busby: C.D. Howe Institute

C.D. Howe Institute Commentary, 2013, issue 396

Abstract: The adoption of new health technologies brings potential improvements to quality of life as well as new costs for provincial healthcare systems. An appropriate evidence-based framework for adoption decisions therefore can go a long way to improving value for money in our health systems. While making decisions to adopt new technologies is a highly politicized process, these decisions must nonetheless strive to make use of all available evidence, including economic evaluations that consider all the costs and consequences of new technologies for society as a whole, including medical, ethical, legal, social and cultural. This Commentary focuses on an emerging, evidence-based policy tool called Health Technology Assessment (HTA). HTA helps inform decisionmaking on how to balance demand and supply pressures for new technologies within a health-system budget. The overarching objective is to obtain the greatest health gains within fiscal constraints by grounding decisions in a clear, transparent and coordinated process. In Canada, the number of entities engaged in various forms of HTA has been growing, and more and more people in healthcare are becoming exposed to the techniques involved. This progress and capacity growth is encouraging. However, rather than counting on a natural slowing of healthcare costs to relieve fiscal pressures, the provinces would be better off grounding their efforts in clear and coordinated HTA processes that incorporate economic evaluation and meaningful collaborative deliberation based on available evidence. This Commentary also looks at examples of HTA experience outside Canada and highlights lessons for Ottawa and the provinces. At present, the National Institute for Health and Care Excellence in the UK is by far the most advanced example of an attempt to utilize a consistent framework for technology adoption in a government-funded healthcare system. The UK’s current transition toward “value-based pricing” is another positive example of how HTA economic evaluation can be used to inform technology adoption in a more constructive way than with traditional “yes” or “no” recommendations. Canadian HTA agencies should draw as much as possible on existing international evidence – from randomized clinical trials, post-market assessments, clinical guidelines, etc. – and maintain close relationships with their counterparts in other countries and international organizations. Finally, HTA frameworks in Canada also must aim to encourage greater stakeholder participation and relationship development.

Keywords: Social Policy; Health Policy (search for similar items in EconPapers)
JEL-codes: I10 I12 I18 O33 (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.cdhowe.org/capturing-value-health-technologies-lean-times (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cdh:commen:396

Access Statistics for this article

More articles in C.D. Howe Institute Commentary from C.D. Howe Institute Contact information at EDIRC.
Bibliographic data for series maintained by Kristine Gray ( this e-mail address is bad, please contact ).